Shares were declining 0.53% to $30.04 early Friday afternoon.
For the three months ended in December, Wall Street is looking for a profit of 52 cents a share on revenue of $13.57 billion.
Results for the fourth quarter of fiscal 2015 are anticipated to be lower than earnings from a year ago of 54 cents a share on revenue of $13.11 billion.
Pfizer recently said it's considering selling the pumps and devices unit it acquired when it bought Hospirafor about $17 billionlast September. If it does, it could generate around $2 billion, but so far, it's still in its early talks and the specifics could change, Bloomberg noted.
Pfizer in November also agreed to buy Botox-maker Allergan (AGN) for $160 billion, creating the largest drug maker in the world.
Separately, TheStreet Ratings currently has a Buy rating on the stock with a letter grade of B.
The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, good cash flow from operations and expanding profit margins.
Recently, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author.
You can view the full analysis from the report here: PFE